Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMSLE03)

Drug Name

PF-562271 Drug Info

Synonyms

PF-00562271

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]

Cross-matching ID

PubChem CID: 11713159
ChEBI ID: CHEBI:91370
CAS Number: CAS 717907-75-0
TTD Drug ID: DMSLE03

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Patented Agent(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Focal adhesion kinase 1 (FAK)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
VS-6063	DMGBLI3	Mesothelioma	2C51.2	Phase 2	[3]
BI-853520	DMNOSYW	Solid tumour/cancer	2A00-2F9Z	Phase 1	[4]
VS-4718	DMN9JCD	Solid tumour/cancer	2A00-2F9Z	Phase 1	[5]
GSK-2256098	DMR24MI	Pulmonary arterial hypertension	BB01.0	Phase 1	[6]
CEP-37440	DMV632P	Solid tumour/cancer	2A00-2F9Z	Phase 1	[4]
IN10018	DMPXOVA	Metastatic melanoma	2E2Z	Phase 1	[7]
1,2,4-triazolo[1,5a]pyridine derivative 1	DMIUPSA	N. A.	N. A.	Patented	[8]
BMS-536924	DMXJB4N	Discovery agent	N.A.	Investigative	[9]
PF-228	DM32FKD	Discovery agent	N.A.	Investigative	[10]
PMID23414845C30	DMNVQ29	Discovery agent	N.A.	Investigative	[11]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Focal adhesion kinase 1 (FAK)	TTON5IT	FAK1_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT00666926) Study Of PF-00562271, Including Patients With Pancreatic, Head And Neck, Prostatic Neoplasms. U.S. National Institutes of Health.
2	Inhibition of focal adhesion kinase by PF-562,271 inhibits the growth and metastasis of pancreatic cancer concomitant with altering the tumor microenvironment. Mol Cancer Ther. 2011 Nov;10(11):2135-45.
3	Role of focal adhesion kinase in regulating YB-1-mediated paclitaxel resistance in ovarian cancer. J Natl Cancer Inst. 2013 Oct 2;105(19):1485-95.
4	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
5	FAK Inhibition disrupts a beta5 integrin signaling axis controlling anchorage-independent ovarian carcinoma growth. Mol Cancer Ther. 2014 Aug;13(8):2050-61.
6	A small molecule FAK kinase inhibitor, GSK2256098, inhibits growth and survival of pancreatic ductal adenocarcinoma cells. Cell Cycle. 2014;13(19):3143-9.
7	Clinical pipeline report, company report or official report of InxMed.
8	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
9	Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitum... J Med Chem. 2005 Sep 8;48(18):5639-43.
10	Cellular characterization of a novel focal adhesion kinase inhibitor. J Biol Chem. 2007 May 18;282(20):14845-52.
11	Structure-based discovery of cellular-active allosteric inhibitors of FAK. Bioorg Med Chem Lett. 2013 Mar 15;23(6):1779-85.